SG11202105861WA - Vectors for protein manufacture - Google Patents

Vectors for protein manufacture

Info

Publication number
SG11202105861WA
SG11202105861WA SG11202105861WA SG11202105861WA SG11202105861WA SG 11202105861W A SG11202105861W A SG 11202105861WA SG 11202105861W A SG11202105861W A SG 11202105861WA SG 11202105861W A SG11202105861W A SG 11202105861WA SG 11202105861W A SG11202105861W A SG 11202105861WA
Authority
SG
Singapore
Prior art keywords
vectors
protein manufacture
protein
manufacture
Prior art date
Application number
SG11202105861WA
Inventor
Gregory T Bleck
Rachel H Kravitz
Chad A Hall
Original Assignee
Catalent Pharma Solutions Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Catalent Pharma Solutions Llc filed Critical Catalent Pharma Solutions Llc
Publication of SG11202105861WA publication Critical patent/SG11202105861WA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
SG11202105861WA 2018-12-04 2019-12-04 Vectors for protein manufacture SG11202105861WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862775194P 2018-12-04 2018-12-04
PCT/US2019/064423 WO2020117910A1 (en) 2018-12-04 2019-12-04 Vectors for protein manufacture

Publications (1)

Publication Number Publication Date
SG11202105861WA true SG11202105861WA (en) 2021-07-29

Family

ID=70974897

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202105861WA SG11202105861WA (en) 2018-12-04 2019-12-04 Vectors for protein manufacture

Country Status (11)

Country Link
US (1) US20220056476A1 (en)
EP (1) EP3891278A4 (en)
JP (1) JP2022510813A (en)
KR (1) KR20210098976A (en)
CN (1) CN113039270A (en)
AU (1) AU2019392554A1 (en)
BR (1) BR112021010785A2 (en)
CA (1) CA3119799A1 (en)
MX (1) MX2021006241A (en)
SG (1) SG11202105861WA (en)
WO (1) WO2020117910A1 (en)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5256568A (en) * 1990-02-12 1993-10-26 Regeneron Phamaceuticals, Inc. Vectors and transformed most cells for recombinant protein production with reduced expression of selectable markers
US20030224415A1 (en) * 2001-06-29 2003-12-04 Gala Design, Inc. Selection free growth of host cells containing multiple integrating vectors
CA2506619A1 (en) * 2002-11-18 2004-08-19 Thomas W. Hodge Cell lines and host nucleic acid sequences related to infectious disease
US7824907B2 (en) * 2003-03-11 2010-11-02 Merck Serono Sa Expression vectors comprising the mCMV IE2 promoter
EP2325322A1 (en) * 2009-11-23 2011-05-25 4-Antibody AG Retroviral vector particles and methods for their generation and use
EP2935581A4 (en) * 2012-12-21 2016-07-27 Merck Sharp & Dohme Expression vectors for recombinant protein production in mammalian cells
KR20170081784A (en) * 2016-01-04 2017-07-13 한국과학기술원 A cell line which is knockout the glutamine synthetase gene and a method of producing target proteins using the above GS knockout HEK293 cell line
SG11201805809WA (en) * 2016-01-06 2018-08-30 Lonza Ag Inhibition of protein degradation for improved production

Also Published As

Publication number Publication date
BR112021010785A2 (en) 2021-11-16
US20220056476A1 (en) 2022-02-24
KR20210098976A (en) 2021-08-11
EP3891278A1 (en) 2021-10-13
AU2019392554A1 (en) 2021-06-03
EP3891278A4 (en) 2022-08-31
WO2020117910A1 (en) 2020-06-11
JP2022510813A (en) 2022-01-28
MX2021006241A (en) 2021-08-11
CA3119799A1 (en) 2020-06-11
CN113039270A (en) 2021-06-25

Similar Documents

Publication Publication Date Title
GB201800903D0 (en) Vectors
DK3737402T3 (en) Modificeret protein
ZA201906235B (en) Csf1r-based chimeric proteins
IL277706A (en) Reprogramming vectors
IL288412A (en) Peptides
IL281088A (en) Flt3l-based chimeric proteins
IL279355A (en) Anti-steap1 antigen-binding protein
ZA202102533B (en) Fusion protein
IL268170A (en) Vsig8-based chimeric proteins
SG11202006140TA (en) Process for providing pegylated protein composition
GB201815670D0 (en) Protein editing
IL284006A (en) Mitochondria-targeting peptides
GB201810052D0 (en) Polypeptide
SG11202105861WA (en) Vectors for protein manufacture
GB201909710D0 (en) Proteins
GB201816644D0 (en) Vectors
GB201806375D0 (en) Vectors
GB201913320D0 (en) Novel proteins
GB201807863D0 (en) Peptides
GB201904756D0 (en) Novel proteins
GB201806181D0 (en) Peptides
IL290019A (en) Melanocyte-regulating peptides
GB201805807D0 (en) Peptides
GB201805809D0 (en) Peptides
GB201805801D0 (en) Peptides